Navigation Links
PAREXEL Announces Date of Second Quarter Fiscal Year 2012 Earnings Release and Conference Call
Date:1/3/2012

BOSTON, Jan. 3, 2012 /PRNewswire/ -- PAREXEL International Corporation (NASDAQ: PRXL) will release financial results for the Second Quarter of Fiscal Year 2012 on Monday, January 30, 2012 after the close of the stock market.  The announcement will be available on PAREXEL's website at www.PAREXEL.com and on the PR Newswire website at www.prnewswire.com.

PAREXEL will host a conference call and live webcast at 10:00 a.m. ET on Tuesday, January 31, 2012 to discuss the results.  To access the webcast, visit PAREXEL's website at www.PAREXEL.com, and click on the Investors menu.  This webcast will continue to be accessible for one year following the live broadcast.  To participate via telephone, dial (408) 940-3886 and ask to join PAREXEL's Second Quarter Fiscal Year 2012 conference call.

About PAREXEL International

PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement.  Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process.  Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 67 locations throughout 52 countries around the world, and has approximately 10,850 employees.  For more information about PAREXEL International visit www.PAREXEL.com.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.

Contacts:
James Winschel, Senior Vice President and Chief Financial Officer
Jill Baker, Corporate Vice President, Investor Relations
+1-781-434-4118
Email: Jill.Baker@PAREXEL.com


'/>"/>
SOURCE PAREXEL International Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PAREXEL Strengthens Late Phase and Observational Research Capabilities With Expert Team to Help Biopharma Meet Commercialization Goals
2. PAREXEL Advances Early Phase CNS Research Capabilities With Leading Medical Imaging Technology
3. UCB and PAREXEL Sign Strategic Partnership Agreement
4. PAREXEL International to Present at Lazard Capital Markets Healthcare Conference and Citi Small/Mid Cap Conference
5. PAREXEL Commercialization Experts to Present Best-Practice Approaches for Demonstrating Product Value at ISPOR Annual European Congress
6. PAREXEL Reports First Quarter Fiscal Year 2012 Financial Results
7. PAREXEL Expands Commercialization Capabilities With Dedicated Team to Help Biopharma Companies Demonstrate Product Value
8. New PAREXEL Podcast Series to Deliver Clinical Development and Commercialization Thought Leadership
9. PAREXEL and National University of Singapore Establish Program in Singapore to Meet Increasing Demand in Asia for Clinical Research Talent
10. PAREXEL Announces Date of First Quarter Fiscal Year 2012 Earnings Release and Conference Call
11. Experts to Provide Successful Strategies for Global Biopharmaceutical Development and Commercialization at PAREXEL Tokyo Seminar
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2017)... -- The Institute for In Vitro Sciences (IIVS), a ... a VITROCELL® inhalation exposure system thanks to a generous ... which is designed to replace animals in inhalation testing, ... airborne test materials in an environment that mimics the ... testing combustible tobacco products, as well as next generation ...
(Date:7/10/2017)... N.C. , July 10, 2017 Locus ... Convertible Note to support the development of CRISPR-Cas3 antimicrobial ... Holdings Limited, a leading Chinese Internet services provider, and ... will advance multiple infectious disease product programs targeting antibiotic ... Founded by Dr. Rodolphe Barrangou ...
(Date:7/5/2017)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ... pharmaceutical company focused on the development of oral drug delivery ... Israel Securities Authority to dual-list its common stock on the ... trading on the TASE on July 12, 2017 under the ... Company, it is expected that Oramed will be included in ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... 2017 , ... Thomas Jefferson University , in collaboration ... a $300,000 grant from The Pew Center for Arts & Heritage to build ... recognition of one’s own limits among health professions students. , The two-year ...
(Date:7/21/2017)... ... July 21, 2017 , ... The Visiting ... the C. R. Bard Foundation, Inc. to support the music therapy ... service available through the nonprofit home care agency. Using evidence-based methods, professionally trained ...
(Date:7/21/2017)... ... July 21, 2017 , ... In the first prospective ACL ... Orthopaedics Outcome Network (MOON) demonstrated that patients could perform sports-related functions and maintain ... decline over time. The study, presented today at the American Orthopaedic Society ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... bone marrow cancer that progresses rapidly without treatment. Newly diagnosed patients face intense ... chance of reoccurrence and relapse. With such a challenging diagnosis that requires ...
(Date:7/20/2017)... (PRWEB) , ... July 20, 2017 , ... Team Type ... access to medicine for everyone affected by diabetes, is teaming up with a Microsoft ... global event kicks off on July 24th. , “Team Type 1’s mission overlaps ...
Breaking Medicine News(10 mins):